Form 4: Surrozen Executive Li Yang Increases Equity Stake

Executive Vice President of Research Li Yang acquired 1,666 shares of Surrozen, Inc. common stock via the employee stock purchase plan.

Summary

• Li Yang, Executive Vice President of Research at Surrozen, Inc., acquired 1,666 shares of common stock.
• The transaction occurred on June 15, 2026, at a price of $8.11 per share.
• The acquisition was made through the company's 2021 Employee Stock Purchase Plan.
• Following this transaction, the reporting person directly owns 18,882 shares of common stock.
• The reporting person also maintains indirect ownership of 702 shares held by family members (351 by daughter, 351 by son).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event, as it reflects routine executive investment in the company's equity.

Positives

• Insider acquisition of company stock signals management confidence in the firm's long-term prospects.
• The transaction was executed through a standard employee benefit plan, indicating alignment with company-sponsored equity programs.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine insider transaction report.

Industry Context

StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed as a positive signal regarding the internal assessment of clinical pipeline progress and corporate stability.

Comparison to Industry Standards

• Insider participation in Employee Stock Purchase Plans (ESPP) is a standard corporate governance practice for aligning executive interests with shareholders.
• The volume of shares acquired is consistent with typical executive participation in such plans.

Stakeholder Impact

• Shareholders may view the increased insider stake as a sign of management commitment.

Key Dates

Keywords

Surrozen, SRZN, Insider Trading, Form 4, Biotech, Equity Purchase